Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centocor Remicade

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

nfliximab receives supplemental approval Dec. 29 for use in combination with methotrexate to inhibit "the progression of structural damage in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate." The agent was previously approved for use with methotrexate to reduce signs and symptoms of RA. For the new indication, Centocor has a Phase IV commitment to conduct a 1,000-patient study on the effects of infliximab on infections. The study, which is expected to begin in September, will assess the standard 3 mg/kg dose and a new 10 mg/kg dose that labeling says may be considered for patients with incomplete responses. A final study report is expected in September 200
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel